NIH-funded research R01 grant

Understanding how a liver hormone (FGF21) is controlled during alcohol use

Official title: Identifying an immunoregulatory axis for FGF21 in alcohol consumption

Funded at Ut Southwestern Medical Center · NIH-11390965 · Data updated 2026-11-12

A study in people with alcohol-related liver disease explores how inflammation in the liver affects a key hormone (FGF21) and whether this process can be targeted to reduce alcohol use and liver damage.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUt Southwestern Medical Center
NIH-funded
Lab location1 site (Dallas, United States)
Project startSeptember 20, 2024
Project endJune 30, 2029
Funding year2026
Award (this year)$537,587
NIH project number5R01AA031460-03
Project IDNIH-11390965 on NIH RePORTER

Who could benefit from this research

Could help

Patients with alcohol use disorder and alcohol-associated liver disease who may benefit from future targeted therapies or biomarkers.

Less likely to help

Individuals without alcohol-related liver disease or without participation in related biomarker or therapeutic studies may not benefit directly.

What this research studies

This project looks at the links between liver inflammation, a hormone called FGF21, and alcohol consumption. Researchers will study cellular and animal models to uncover how IRF3 and PLAGL1 influence FGF21 levels during alcohol exposure, and how this interaction might drive ALD progression. The goal is to identify mechanisms that could be targeted to develop new treatments that help people reduce drinking and protect the liver. Findings could pave the way for therapies that support better liver health in those affected by alcohol use disorders.

Why it matters

Potential benefit: If successful, the work could lead to new therapies that boost protective liver signals and help people reduce alcohol intake and prevent ALD progression.

How similar studies have gone: Prior research has shown that inflammatory pathways influence liver metabolism and that FGF21 is connected to alcohol responses, with this study aiming to translate those findings into potential treatments.

Where this research is happening

  • Ut Southwestern Medical Center
    Dallas, United States
    Active

Researchers

  • Principal investigator: Patel, Suraj J — Ut Southwestern Medical Center
  • Study coordinator: Patel, Suraj J

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.